Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 478963

The company stated that HeFH trial also showed patients taking torcetrapib/atorvastatin experienced an average rise of about 2 millimeters in systolic blood pressure, versus patients on atorvastatin alone. The company indicated that HeFH study in patients with an increased risk of heart disease, will be presented at the American Heart Association Annual Scientific Sessions on November 15. Dr.

Joseph, chief medical officer of Pfizer said the phase 3 results to date are incomplete and added, "the early results cover less than 25 percent of all the patients in the entire clinical program. With a new abstract being posted today we want to ensure that these results are put in the appropriate perspective." Dr.

Joseph noted that no final conclusions on the efficacy and safety of torcetrapib/atorvastatin could be derived until the lipid and imaging studies are concluded and the accompanying statistics are analyzed. The torcetrapib/atorvastatin trials completed to date vary in duration and size, and preliminary data at this stage may not represent the final results when Phase 3 is completed, he further added. The company stated that the next release of clinical trial results would take place in March at the American College of Cardiology meetings, when the results of three vascular imaging studies will be released.

The shares of PFE is currently trading down 0.58% at $26.62.